AREG and ovarian cancer: In addition, a monoclonal antibody blocking ADAM17 activity inhibited shedding of the ADAM17 substrates TNF, TNFR1-alpha, TGF-alpha, AREG, HB-EGF and IL-6Ralpha and reduced tumor growth, in an ovarian cancer xenograft model [24].